The objective of this study was to investigate the relationship between the genetic polymorphism of the serotonin transporter gene-linked polymorphic region (5-HTTLPR)and the response to citalopram treatment and side effects in Turkish patients with major depressive disorder. The study involved 51 patients who received 10-40 mg/day of citalopram for 4 to 6 weeks. Clinical symptoms were evaluated by the 17-item Hamilton Depression Rating (HAMD-17) scale, Clinical Global Impression (CGI) and UKU side effect rating scale (UKU) at weeks 4 and/or 6. The 5-HTTLPRL/S polymorphism was determined by slowdown-polymerase chain reaction method. Of the fifty-one patients, 13 (26%) were the LL genotype, 21 (41%) were the LS genotype, 17 (33%) were the SS genotype. L allele seems to be associated withbetter response due to odds ratio for L allele versus S allele despite statistically insignificant. In terms of CGI-Severity scale, The LL genotype versus the LS genotype had a higher risk at the week 6 (P<0.05).On the other hand, apart from this comparison, there is no significant difference in CGI-Severity and Improvement and UKU scales according to the distribution of genotypes at week 4 and/or 6. However, these findings surely need further investigation and confirmation. 
INTRODUCTION
Major depressive disorder (MDD, major or unipolar depression) affects over 340 million people worldwide (1) and is an important clinical problem that has a lifetime risk in 15-20% of the general populations (2) . The prevalence of MDD is twice in women than men (2) and the lifetime prevalance is 10-25% in women and 5-12% in men (3) . The prevalence of MDD is on the rise. It has been predicted that MDD would be the second leading cause of death and disability by the year 2020 (4) .
The selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for mild to severe MDD (5) . However, approximately 30-40% of patients with depression do not sufficiently respond to treatment with SSRIs (5) .Generally, it can be determined whether an antidepressant drug is effective or ineffective after 4-6 weeks of treatment (6) . However, this extensive period increases the cost of treatment (7) . Therefore, recently, treatment response in MDD has become a popular topic to pharmacogenetic studies.
The principal site of action of SSRIs is the serotonin transporter (5-hydroxytryptamine transporter, 5-HTT, SERT, SLC6A4) andthese drugs inhibit5-HTT(5). 5-HTT is a member of the family of the Na + /Cl --dependent membrane transporters and controls the spread of the serotonergic signal in time and space by reuptake of serotonin (5-hydroxytryptamine, 5-HT)that exerts its effects immediately after its release from the synaptic cleft (8) . Thus,5-HTT is the first candidate of approaching a genetic predictor of response to SSRIs. The human gene-encoding serotonin transporter is located on chromosome 17q11.1-q12, spans 31 kb and consists of 14 exons.The most common polymorphisms in 5-HTT gene are insertion/deletion and VNTR polymorphisms (8) . In this study, the insertion-deletion polymorphism was investigated. The common length polymorphism, termed the 5-HTT-linked polymorphic region (5-HTTLPRor SERTPR), is constituted by an insertion-deletion of 44 bp in the promoter region (9) and thereupon, results in a short (S, 484 bp) and long (L, 528 bp) polymorphisms. It has been shown that these alleles can alter transcription and functional capacity of 5-HTT (9, 10) . S allele is known to be associated with decreased transcriptional activity of the 5-HTT gene and lowered 5-HTT expression (11)Polymorphisms havealso been determined to play a role in theetiology and outcome of several psychiatric disorders including anxiety disorders, mood disorders, schizophrenia as well as autism (10, (12) (13) (14) and some psychosomatic disorders (13) .
The objective of this study was to investigate the relationship between the 5-HTTLPR polymorphism and the response to citalopram treatment and side effects in Turkish patients with MDD.
MATERIAL AND METOD

Subjects
The present investigation was conducted in 51 Turkish patients receiving 10-40 mg/day citalopram at the Departments of Psychiatry, Schools of Medicine, Ankara University and Kırıkkale University, Turkey. The presence of MDD was diagnosed with the structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) (15) . Inclusion criteria were meeting DSM-IV diagnosis of MDD, being under stable citalopram medication regimen (for at least 4 weeks). All participants were aged 18 to 65.Exclusion criteria were as follows; pregnancy, substance dependency or drug abuse, and ongoing treatment with any other antidepressant or antipsychotic, history of head trauma with loss of consciousness.The study protocol was approved by the Ethics Committee of the Ankara University and conducted in accordance with Good Clinical Practices and the Helsinki declaration. Informed written consent was obtained from each patient before participating in the study.
Blood sampling
Blood samples (10 ml) were taken from using EDTA vacutainer tubes between 08:00 and 09:00 a.m. at the 4th and/or 6th weeks before the daily dose of citalopram. Genomic DNA was extracted from the cell fraction immediately by use of the Wizard Genomic DNA Purification Kit (Promega, Madison, WIS, USA). DNA yields were estimated by measuring the absorbance at 260 nm (A260). All samples were stored at -80°C until analysis.
Genotyping
The 5-HTTLPR polymorphism was identified by slowdown-polymerase chain reaction (PCR) method according to Frey et al. (16) with minor modifications. The primers employed wereF:
5'-GGCGTTGCCGCTCTGAATGC-3', R: 5'-GAGGGACTGAGCTGGACAACCAC-3' (10). Each reaction mixture (25 μl) contained ~ 100 ng of DNA template, 10 pmol of each primer, 0.2 mM each deoxynucleotide triphosphate, 10 x PCR buffer, 2.5 mM MgCl 2 , and 1.25 unit of Taq polymerase (Fermentase) on the MBS Satellite Thermal Cycler (Thermo, UK). Negative control reactions with no added DNA were included in each slowdown-PCR analysis to ensure the reagents used contained no contaminating DNA. The slowdown-PCR product was analyzed electrophoretically on a 2% Gamma prona agarose gel stained with ethidium bromide (500 ng/ml). Alleles were designated as short (484 bp) and long (528 bp) against a DNA marker in genotyping for the 5-HTTLPRpolymorphism.
Clinical measures
Clinical symptoms were evaluated by the 17-item Hamilton Depression Rating (HAMD-17) Scale and Clinical Global Impression Scale (CGI) was employed to assess severity of illness and global improvement of symptoms (17) . Furthermore, the presence and severity of side effects was assessed by using the UKU scale which included four subscales: psychic, neurological, autonomic, and "other" (18) . These evaluations were done at baseline and weeks 4 and/or 6 of treatment.Responders were defined as those subjects with a decrease in HAMD score by ≥50% from the baseline to weeks4 and/or 6.
Statistical analysis
Allele and genotype frequencies were calculated by genotype counting method. The observed genotype frequencies of 5-HTTLPR were compared with the expected frequencies according to Hardy-Weinberg equilibrium. The comparison of demographic and clinical data among the 5-HTTLPR genotypes was done using chi-square test (X 2 ) and one-way analysis of variance test (One-Way ANOVA), as appropriate.For One-Way ANOVA test, means were compared using Duncans multiple range post hoc test.Statistical analyses were performed using SPSS for Windows 11.5 software. A P value <0.05 was considered as statistically significant.
RESULTS
The5-HTTLPR polymorphisms analysis was conducted with 51 Turkish patients with MDD. Table 1 shows baseline characteristics of the patients according to 5-HTTLPR polymorphisms. Table 1 .Baseline characteristics of the patients with major depression according to 5-HTTLPR polymorphisms
51 (100) 13 (26) 21 (41) 17 ( Of the fifty-one patients, 86 % of patients were female, whereas 14% of them were male (p>0.05) and 13 (26%) were homozygous for the L allele, 21 (41%) were heterozygous, and 17 (33%) were homozygous for the S allele.
Of the fifty-one participants, treatment response was assessed in 46 patients because 5participants dropped out. As depicted in Table 2 ,36 (78%) subjects were determined to be treatment responders (R+) and 10 (22%) were nonresponders (R-). Of the 36 R+ subjects and the 10 R-subjects, 9 (25%) and 1 (10%) had LL genotypes, 15 (42%) and 5 (50%) had LS genotypes, 12 (33%) and 4 (40%) had SS genotypes, respectively.R+ and R-subjects were not different in terms of polymorphisms (P>0.05).However, the results were observed that odds ratios (ORs) for LL + LS genotypes versus SS genotypes and L allele versus S allele were 1.333 (95% CI 0.251-6.929, p>0.05), and 1.571 (95% CI 0.506-4.987, P>0.05), respectively. Table 3 . In terms of CGI-Severity,the LS genotype versus the LL genotype had 4.44 times higher risk at week 4 although statistically insignificant. However, the LL genotype versus the LS genotype had 6.50 times higher risk at the week 6 and this comparison was statistically significant (P<0.05).L allele versus S allele had 2.70 times higher risk at week 4 and 6,inspite of statistically insignificant. On the other hand, in terms ofCGI-Improvement, the LS genotype and the SS genotype versus the LL genotype at week 4 had 2.10 and 2.33 times higher risk, respectively, despite statistically insignificant. Table 4 has shown UKU side effect rating subscale and ORs according to 5-HTTLPR promoter polymorphism. The presence and severity of side effects was assessed by using the UKU scale which included foursubscales: psychic, neurological, autonomic, and "other" (18) at the end of the 4 th week of pharmacological treatment.As depicted in Table 4 , the LL genotype and the LS genotype versus the SS genotype had3.21 times and 2.32 times higher risk for UKU psychic subscale, respectively. For UKU autonomic subscale, patients with the SS genotype versus the LL genotype had 2.80 times higher risk. For UKU "other" subscale, patients with the LL genotype versus the SS genotype had 2.00 times higher risk. However, these comparisons were statistically insignificant (P>0.05). 
DISCUSSION
Baseline characteristics of the patients with major depression
In the present study, we assessed baseline characteristics of the patients with major depression according to 5-HTTLPR polymorphisms as depicted in Table 1 . Age, gender and marital status are found to be associated with depression as a result of epidemiological studies in different countries (19) .The risk of MDD is generally higher in women than men (2,3,19) .Furthermore, the proportion of major depression is significantly higher in individuals who are divorced or separated compared to the married individuals (19) . The results of major depression related to age may be inconsistent. According to some studies, the prevalence of major depression decrease with age (19) . Whereas, other studies found that major depression is increased with age (19) .In this study, education level, marital and employment status were comparable among different polymorphism groups and this enables a clear discussion of our results.
Correlation between 5-HTTLPR genotypes and response to citalopram treatment
Much recent research has focused on identifying genetic predictors of treatment response. The variability in interindividual pharmacological response give rise to different problems of efficacy and safety, especially in psychopharmacotherapy (20) . Therefore, genetic factors seem to be biomarkers of responses to treatment (21) .
To the best of our knowledge, the study was the first to investigate the association between 5-HTTLPR promoter polymorphism and response to citalopram treatment in Turkish population. It has been reached predictive information that subjects having L allele might have better response to citalopram treatment than those having S allele because odds ratio for L allele versus S allele was 1.571 in spite of statistically insignificance. Our results were in accordance with most of the studies in Caucasian -and not Oriental -populations (Table5).Significant associations between the long variant and good treatment response have been reported in most of studies performed in Caucasian populations. On the other hand, the SS genotypes were reported to be more likely to respond in the studies performed in Oriental populations. However, findings in both inter-ethnicity and intra-ethnicity have not always been consistent as shown in Table 5 . There are several possible explanations for this discrepancy. First, the frequencies of L and S alleles are different between Caucasian and Oriental populations. The frequencies of the LL genotype and the SS genotype in Caucasian are 29-43% (47) and 21.6 to 28.3% (48) , respectively while those in Oriental populations are 1-13% (47), 55.6 and 60.0% (48) , respectively. The L allele is present ~55 % in Caucasians and ~ 25 % in Oriental populations, respectively (40) . The S allele is present in 42% in Caucasians and 79% in Oriental populations, respectively (49) . Secondly, other polymorphisms in the 5-HTT gene or other relevant genes may be possible factors and and were not assessed in the present study.Finally, the interactions between 5-HTTLPR genotype and the other genes, drug plasma concentration, life events and gender may bepossible factors (50) .As a result, it may be concluded that 5-HTTLPR may be a biomarker of response to antidepressant in Caucasians, but it does not appear to play a main role in Oriental populations.
In this study, we also investigated the relationship between the 5-HTTLPR genotypes and CGI-Severity&Improvement. Interestingly, our results suggested that patients with the LL genotype or L allele had higher disease severitythan patients with the SS genotype or S allele. Furthermore, the LS and/or SS genotypes hadin favour for CGI-improvement than the LL genotype. However, there is no significant difference in either CGI-severity orCGIimprovement according to the distribution of genotypes at week 4 and 6 except that the comparison of LL genotype to the LS genotype at the week 6 in terms of CGI-Severity scale (P<0.05).
The association between the 5-HTTLPR polymorphism and side effects
Side effectsareamong primary reason to incompliance in SSRI treatment. The present study, 84% of patients had side effects but the remaining 16% had not. 57, 55 and 53% of patients had side effects in terms of psychic, autonomic and "other" subscale, respectively. The most frequently reported psychic side effects were sleepiness/sedation (38%), increased duration of sleep (28%) and reduced duration of sleep (17%). The most common autonomic side effects were nause/vomiting (39.3%), palpitations/tachycardia (28.5%), increased tendency to sweating (25%) and constipation (18%). Furthermore, headache (37%) and sexual dysfunction (increased sexual desire plus diminished sexual desire) (37%) were the most often declared side effects among "other" subscale. These results are in accordance with those of previous studies related to the frequent of side effects during SSRIs (51,52).
Our findings suggested that patients with the LL genotype and the LS genotype versus the SS genotype had a higher risk for psychic side effects. For UKU "other" subscale, the LL genotype versus the SS genotype had a higher risk. Whereas, for autonomic side effects, the SS genotype versus the LL genotype were under a higher risk. Nevertheless, comparison of the subjects with the LL genotype and those with the LS and SS genotypes revealed no significant differences in the UKU side effect rating subscale at week 4.
Side effects can berelated tostimulation of different serotonin receptors. For instance, the 5HT2 receptors are thought to have a role in mood, anxiety, sexual function, sleep, eating behavior (53) . Moreover, the 5HT3 receptors are involved in nause, vomiting, appetite and GI motility (Stahl, 1998) . The 5-HTTLPR polymorphism may moderate some of SSRI-induced side effects caused by increased serotonin levels and stimulation of serotonin receptors. However, this hypothesis that the 5-HTTLPR genotype plays a certain role in inducing side effects during SSRI treatment is unclear (52) .
The main limitation of our study was the small samplesize. The amount of patients with variant alleles, female/male ratio, etc. were not high and socio demographic features were comparable among different polymorphism groups. Nevertheless, our findings is in accordance with some of previous studies findings in Caucasians. Moreover, the study provides valuable information because the study was the first to investigate the association between5-HTTLPR promoter polymorphism and response to citalopram treatment in Turkish population.
CONCLUSION
Consequently, our findings suggest that L allele tend for better response due to acceptable odds ratio values for L allele versus S allele despite statistically insignificant. Moreover, there is no significant difference in CGI and UKU according to the distribution of genotypes at week 4 and/or6 except that the comparison of LL genotype to the LS genotype at the week 6 in terms of CGI-Severity scale (P<0.05). However, larger study populations are definetely required to confirm these findings.
